Oral semaglutide has a terminal half-life of roughly a week, and the 2-week gap before we restarted it was not long enough to clear the drug
It has been referenced in the literature as a triple-receptor agonist and studied in the context of metabolic signalling pathways, energy homeostasis, and receptor pharmacology
Position & View: With the patient in RLD (right-lateral decubitus), identify the antrum between left lobe liver and pancreas
Both drugs are dual GIP and GLP-1 receptor agonists, yet each has specific FDA approvals for separate conditions
The rising prevalence of type 2 diabetes and obesity, innovations such as oral formulations and long-acting drugs, increased patient awareness, and regulatory approvals drive the GLP-1 Analogues market
For those who prefer taking it with meals, consider timing it with a meal rich in sulfur-containing foods